Management of sickle cell disease: a review for physician education in Nigeria (sub-saharan Africa)

Ademola Samson Adewoyin, Ademola Samson Adewoyin

Abstract

Sickle cell disease (SCD) predominates in sub-Saharan Africa, East Mediterranean areas, Middle East, and India. Nigeria, being the most populous black nation in the world, bears its greatest burden in sub-Saharan Africa. The last few decades have witnessed remarkable scientific progress in the understanding of the complex pathophysiology of the disease. Improved clinical insights have heralded development and establishment of disease modifying interventions such as chronic blood transfusions, hydroxyurea therapy, and haemopoietic stem cell transplantation. Coupled with parallel improvements in general supportive, symptomatic, and preventive measures, current evidence reveals remarkable appreciation in quality of life among affected individuals in developed nations. Currently, in Nigeria and other West African states, treatment and control of SCD are largely suboptimal. Improved knowledge regarding SCD phenotypes and its comprehensive care among Nigerian physicians will enhance quality of care for affected persons. This paper therefore provides a review on the aetiopathogenesis, clinical manifestations, and management of SCD in Nigeria, with a focus on its local patterns and peculiarities. Established treatment guidelines as appropriate in the Nigerian setting are proffered, as well as recommendations for improving care of affected persons.

References

    1. Modell B., editor. Guidelines for the Control of Haemoglobin Disorders. Sardinia, Italy: WHO; 1989.
    1. Serjeant G. R. Sickle-cell disease. The Lancet. 1997;350(9079):725–730. doi: 10.1016/s0140-6736(97)07330-3.
    1. Modell B., Darlison M. Global epidemiology of haemoglobin disorders and derived service indicators. Bulletin of the World Health Organization. 2008;86(6):480–487. doi: 10.2471/blt.06.036673.
    1. World Health Organisation 2008. Management of haemoglobin disorders. Proceedings of the Report of Joint WHO-TIF Meeting; November 2007; Nicosia, Cyprus.
    1. Piel F. B., Patil A. P., Howes R. E., et al. Global epidemiology of Sickle haemoglobin in neonates: a contemporary geostatistical model-based map and population estimates. The Lancet. 2013;381(9861):142–151. doi: 10.1016/s0140-6736(12)61229-x.
    1. WHO Regional office for Africa. Sickle cell disease prevention and control, 2013, .
    1. Serjeant G. R., Serjeant B. E. The epidemiology of sickle cell disorder: a challenge for Africa. Archives of Ibadan Medicine. 2001;2(2):46–52. doi: 10.4314/aim.v2i2.34560.
    1. Okwi A. L., Byarugaba W., Ndugwa C. M., Parkes A., Ocaido M., Tumwine J. K. An up-date on the prevalence of sickle cell trait in Eastern and Western Uganda. BMC Blood Disorders. 2010;10, article 5 doi: 10.1186/1471-2326-10-5.
    1. Fleming A. F., Storey J., Molineaux L., Iroko E. A., Attai E. D. Abnormal haemoglobins in the Sudan savanna of Nigeria. I. Prevalence of haemoglobins and relationships between sickle cell trait, malaria and survival. Annals of Tropical Medicine and Parasitology. 1979;73(2):161–172.
    1. Uzoegwu P. N., Onwurah A. E. Prevalence of haemoglobinopathy and malaria diseases in the population of old Aguata Division, Anambra State, Nigeria. Biokemistri. 2003;15(2):57–66.
    1. Nwogoh B., Adewoyin A. S., Iheanacho O. E., Bazuaye G. N. Prevalence of haemoglobin variants in Benin City, Nigeria. Annals of Biomedical Sciences. 2012;11(2):60–64.
    1. Horton J. A. B. The Diseases of Tropical Climates and Their Treatment. London, UK: Churchill; 1874.
    1. Herrick J. B. Peculiar elongated and sickle-shaped red blood corpuscles in a case of severe anemia. Archives of Internal Medicine. 1910;6(5):517–521. doi: 10.1001/archinte.1910.00050330050003.
    1. Beutler E. Disorders of haemoglobin structure: sickle cell anaemia and related abnormalities. In: Lichtman M. A., Williams W. J., editors. Williams Haematology. Vol. 47. New York, NY, USA: McGraw-Hill; 2006. pp. 667–700.
    1. Serjeant G. R. The natural history of sickle cell disease. Cold Spring Harbor Perspectives in Medicine. 2013;3(10) doi: 10.1101/cshperspect.a011783.a011783
    1. Pagnier J., Mears J. G., Dunda-Belkhodja O., et al. Evidence for the multicentric origin of the sickle cell hemoglobin gene in Africa. Proceedings of the National Academy of Sciences of the United States of America. 1984;81(6 I):1771–1773. doi: 10.1073/pnas.81.6.1771.
    1. Kulozik A. E., Wainscoat J. S., Serjeant G. R., et al. Geographical survey of β(S)-globin gene haplotypes: evidence for an independent Asian origin of the sickle-cell mutation. American Journal of Human Genetics. 1986;39(2):239–244.
    1. Lapoumeroulie C., Dunda O., Ducrocq R., et al. A novel sickle gene of yet another origin in Africa: the Cameroon type. Human Genetics. 1992;89(3):333–337.
    1. Steinberg M. H. Predicting clinical severity in sickle cell anaemia. British Journal of Haematology. 2005;129(4):465–481. doi: 10.1111/j.1365-2141.2005.05411.x.
    1. Modell B., Darlison M., Birgens H., et al. Epidemiology of haemoglobin disorders in Europe: an overview. Scandinavian Journal of Clinical and Laboratory Investigation. 2007;67(1):39–69. doi: 10.1080/00365510601046557.
    1. Desai D., Dhanani H. Sickle cell disease: history and origin. The Internet Journal of Hematology. 2003;1(2)
    1. Allison A. C. Protection afforded by sickle-cell trait against subtertian malareal infection. British Medical Journal. 1954;1(4857):290–294. doi: 10.1136/bmj.1.4857.290.
    1. Madigan C., Malik P. Pathophysiology and therapy for haemoglobinopathies; Part I: sickle cell disease. Expert Reviews in Molecular Medicine. 2006;8(9):1–23. doi: 10.1016/j.ejcsup.2006.04.072.
    1. Lal A., Vinchinsky E. P. Sickle cell disease. In: Hoffbrand A. V., Catovsky D., Tuddenham E. G. D., Green A. R., editors. Postgraduate Haematology. 6th. Vol. 7. Blackwell Publishing; 2011. pp. 109–125.
    1. Odièvre M.-H., Verger E., Silva-Pinto A. C., Elion J. Pathophysiological insights in sickle cell disease. Indian Journal of Medical Research. 2011;134(10):532–537.
    1. Rosse W. F., Narla M., Petz L. D., Steinberg M. H. New views of sickle cell disease pathophysiology and treatment. Haematatogy. 2000;2000(1):2–17.
    1. Steinberg M. H. Management of sickle cell disease. The New England Journal of Medicine. 1999;340(13):1021–1030. doi: 10.1056/nejm199904013401307.
    1. Frenette P. S. Sickle cell vasoocclusion: heterotypic, multicellular aggregations driven by leukocyte adhesion. Microcirculation. 2004;11(2):167–177. doi: 10.1080/10739680490278556.
    1. Brittain J. E., Parise L. V. The α4β1 integrin in sickle cell disease. Transfusion Clinique et Biologique. 2008;15(1-2):19–22. doi: 10.1016/j.tracli.2008.03.013.
    1. Brittain J. E., Han J., Ataga K. I., Orringer E. P., Parise L. V. Mechanism of CD47-induced α4β1 integrin activation and adhesion in sickle reticulocytes. The Journal of Biological Chemistry. 2004;279(41):42393–42402. doi: 10.1074/jbc.m407631200.
    1. Elion J. E., Brun M., Odièvre M. H., Lapouméroulie C. L., Krishnamoorthy R. Vaso-occlusion in sickle cell anemia: role of interactions between blood cells and endothelium. Hematology Journal. 2004;5(3):S195–S198. doi: 10.1038/sj.thj.6200452.
    1. Ahmed S. G. The role of infection in the pathogenesis of vaso-occlusive crisis in patients with sickle cell disease. Mediterranean Journal of Hematology and Infectious Diseases. 2011;3(1) doi: 10.4084/mjhid.2011.028.e2011028
    1. Fasola F., Adedapo K., Anetor J., Kuti M. Total antioxidants status and some hematological values in sickle cell disease patients in steady state. Journal of the National Medical Association. 2007;99(8):891–894.
    1. Westerman M., Pizzey A., Hirschman J., et al. Microvesicles in haemoglobinopathies offer insights into mechanisms of hypercoagulability, haemolysis and the effects of therapy. British Journal of Haematology. 2008;142(1):126–135. doi: 10.1111/j.1365-2141.2008.07155.x.
    1. Roseff S. D. Sickle cell disease: a review. Immunohematology. 2009;25(2):67–74.
    1. Hsieh M. M., Tisdale J. F., Rodgers G. P. Haemolytic anaemia: thalassemias and sickle cell disorders. In: Rodgers G. P., Young N. S., editors. The Bethesda Handbook of Clinical Haematology. 3rd. Vol. 4. Philadelphia, Pa, USA: Lippincott Williams & Wilkins; 2013. pp. 37–56.
    1. Frenette P. S., Atweh G. F. Sickle cell disease: old discoveries, new concepts, and future promise. The Journal of Clinical Investigation. 2007;117(4):850–858. doi: 10.1172/jci30920.
    1. Hebbel R. P., Osarogiagbon R., Kaul D. The endothelial biology of sickle cell disease: inflammation and a chronic vasculopathy. Microcirculation. 2004;11(2):129–151. doi: 10.1080/10739680490278402.
    1. Kato G. J., Gladwin M. T., Steinberg M. H. Deconstructing sickle cell disease: reappraisal of the role of hemolysis in the development of clinical subphenotypes. Blood Reviews. 2007;21(1):37–47. doi: 10.1016/j.blre.2006.07.001.
    1. Walker T. M., Dunn D. T., Serjeant G. R. The metacarpal index in homozygous sickle-cell disease. British Journal of Radiology. 1988;61(724):280–281. doi: 10.1259/0007-1285-61-724-280.
    1. Stevens N. C. G., Hayes R. J., Serjeant G. R. Body shape in young children with homozygous sickle cell disease. Pediatrics. 1983;71(4):610–614.
    1. Oredugba F. A., Savage K. O. Anthropometric finding in Nigerian children with sickle cell disease. Pediatric Dentistry. 2002;24(4):321–325.
    1. Platt O. S., Thorington B. D., Brambilla D. J., et al. Pain in sickle cell disease: rates and risk factors. The New England Journal of Medicine. 1991;325(1):11–16. doi: 10.1056/nejm199107043250103.
    1. Vijay V., Cavenagh J. D., Yate P. The anaesthetist's role in acute sickle cell crisis. British Journal of Anaesthesia. 1998;80(6):820–828. doi: 10.1093/bja/80.6.820.
    1. Delicou S., Maragkos K. Pain management in patients with Sickle cell disease—a review. European Medical Journal. 2013;1:30–36.
    1. Ballas S. K. Current issues in sickle cell pain and its management. ASH Education Book. 2007;2007(1):97–105. doi: 10.1182/asheducation-2007.1.97.
    1. Yale S. H., Nagib N., Guthrie T. Approach to the vaso-occlusive crisis in adults with sickle cell disease. American Family Physician. 2000;61(5):1349–1356.
    1. Okpala I., Tawil A. Management of pain in sickle-cell disease. Journal of the Royal Society of Medicine. 2002;95(9):456–458. doi: 10.1258/jrsm.95.9.456.
    1. Solomon L. R. Pain management in adults with sickle cell disease in a medical center emergency department. Journal of the National Medical Association. 2010;102(11):1025–1032.
    1. Rees D. C., Olujohungbe A. D., Parker N. E., Stephens A. D., Telfer P., Wright J. Guidelines for the management of the acute painful crisis in sickle cell disease. British Journal of Haematology. 2003;120(5):744–752. doi: 10.1046/j.1365-2141.2003.04193.x.
    1. Davies S. C., Brozovic M. The presentation, management and prophylaxis of sickle cell disease. Blood Reviews. 1989;3(1):29–44. doi: 10.1016/0268-960X(89)90023-4.
    1. Adewoye A. H., Nolan V., McMahon L., Ma Q., Steinberg M. H. Effectiveness of a dedicated day hospital for management of acute sickle cell pain. Haematologica. 2007;92(6, article 854) doi: 10.3324/haematol.10757.
    1. Benjamin L. J., Swinson G. I., Nagel R. L. Sickle cell anemia day hospital: an approach for the management of uncomplicated painful crises. Blood. 2000;95(4):1130–1137.
    1. Ware M. A., Hambleton I., Ochaya I., Serjeant G. Day-care management of sickle cell painful crisis in Jamaica: a model applicable elsewhere? British Journal of Haematology. 1999;104(1):93–96. doi: 10.1046/j.1365-2141.1999.01160.x.
    1. Hassell K. L., Eckman J. R., Lane P. A. Acute multiorgan failure syndrome: a potentially catastrophic complication of severe sickle cell pain episodes. The American Journal of Medicine. 1994;96(2):155–162. doi: 10.1016/0002-9343(94)90136-8.
    1. Akingbola T. S., Kolude B., Aneni E. C., et al. Abdominal pain in adult sickle cell disease patients: a Nigerian experience. Annals of Ibadan Postgraduate Medicine. 2011;9(2):100–104.
    1. Akinola N. O., Bolarinwa R. A., Faponle A. F. The import of abdominal pain in adults with sickle cell disorder. West African Journal of Medicine. 2009;28(2):83–86.
    1. Ebert E. C., Nagar M., Hagspiel K. D. Gastrointestinal and hepatic complications of sickle cell disease. Clinical Gastroenterology and Hepatology. 2010;8(6):483–489. doi: 10.1016/j.cgh.2010.02.016.
    1. Galacteros F., de Montalembert M. Sickle cell disease: a short guide to management. In: Beaumont C., Beris P., Beuzard Y., Brugnara C., editors. ESH Handbook on Disorders of Erythropoiesis, Erythrocytes and Iron Metabolism. Vol. 13. 2009. pp. 276–309.
    1. Odunvbun M. E., Adeyekun A. A. Ultrasonic assessment of the prevalence of gall stones in sickle cell disease children seen at the University of Benin Teaching Hospital, Benin City, Nigeria. Nigerian Journal of Paediatrics. 2014;41(4):370–374. doi: 10.4314/njp.v41i4.16.
    1. Agholor C. A., Akhigbe A. O., Atalabi O. M. The prevalence of cholelithiasis in Nigerians with sickle cell disease as diagnosed by ultrasound. British Journal of Medicine and Medical Research. 2014;4(15):2866–2873. doi: 10.9734/bjmmr/2014/8645.
    1. National Heart. The Management of Sickle Cell Disease. National Institutes of Health; 2002. (NIH Publication 02-2117).
    1. Iheanacho M. C., Akanmu A. S., Nwogoh B. Seroprevalence of human parvovirus B19 antibody in paediatric sickle cell disease patients seen at the Lagos University Teaching Hospital. Annals of Biomedical Sciences. 2014;13(1):123–129.
    1. Hoffbrand A. V., Moss P. A. H., Pettit J. E., editors. Essential Haematology. 5th. Vol. 6. Southampton, UK: Blackwell Publishing; 2006. Genetic disorders of haemoglobin; pp. 72–93.
    1. Akinbami A., Dosunmu A., Adediran A., et al. Steady state hemoglobin concentration and packed cell volume in homozygous sickle cell disease patients in Lagos, Nigeria. Caspian Journal of Internal Medicine. 2012;3(2):405–409.
    1. Adams R. J., Mckie V. C., Su L. H., et al. Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography. The New England Journal of Medicine. 1998;339:5–11.
    1. Platt O. S. Preventing stroke in sickle cell anemia. The New England Journal of Medicine. 2005;353(26):2743–2745. doi: 10.1056/nejmp058274.
    1. Ware R. E., Zimmerman S. A., Schultz W. H. Hydroxyurea as an alternative to blood transfusions for the prevention of recurrent stroke in children with sickle cell disease. Blood. 1999;94(9):3022–3026.
    1. George I. O., Frank-Biggs A. I. Stroke in Nigerian children with sickle cell anaemia. Journal of Public Health and Epidemiology. 2011;3(9):407–409.
    1. Oniyangi O., Ahmed P., Otuneye O. T., et al. Strokes in children with sickle cell disease at the National Hospital, Abuja, Nigeria. Nigerian Journal of Paediatrics. 2013;40(2):158–164.
    1. Ferster A., Tahriri P., Vermylen C., et al. Five years of experience with hydroxyurea in children and young adults with sickle cell disease. Blood. 2001;97(11):3628–3632. doi: 10.1182/blood.V97.11.3628.
    1. Powars D., Wilson B., Imbus C., Pegelow C., Allen J. The natural history of stroke in sickle cell disease. The American Journal of Medicine. 1978;65(3):461–471. doi: 10.1016/0002-9343(78)90772-6.
    1. Lagunju I. A., Brown B. J., Sodeinde O. O. Chronic blood transfusion for primary and secondary stroke prevention in Nigerian children with sickle cell disease: a 5-year appraisal. Pediatric Blood and Cancer. 2013;60(12):1940–1945. doi: 10.1002/pbc.24698.
    1. Miller S. T., Wright E., Abboud M., et al. Impact of chronic transfusion on incidence of pain and acute chest syndrome during the Stroke Prevention Trial (STOP) in sickle-cell anemia. The Journal of Pediatrics. 2001;139(6):785–789. doi: 10.1067/mpd.2001.119593.
    1. McCavit T. L., Xuan L., Zhang S., Flores G., Quinn C. T. National trends in incidence rates of hospitalization for stroke in children with sickle cell disease. Pediatric Blood & Cancer. 2013;60(5):823–827. doi: 10.1002/pbc.24392.
    1. Strouse J. J., Lanzkron S., Urrutia V. The epidemiology, evaluation and treatment of stroke in adults with sickle cell disease. Expert Review of Hematology. 2011;4(6):597–606. doi: 10.1586/ehm.11.61.
    1. Wang W. C. The pathophysiology, prevention, and treatment of stroke in sickle cell disease. Current Opinion in Hematology. 2007;14(3):191–197. doi: 10.1097/MOH.0b013e3280ec5243.
    1. Mayberg M. R., Batjer H. H., Dacey R., et al. Guidelines for the management of aneurysmal subarachnoid hemorrhage. Stroke. 1994;25(11):231–232. doi: 10.1161/01.str.25.11.2315.
    1. Platt O. S. Prevention and management of stroke in sickle cell anemia. Hematology. 2006:54–57.
    1. DeBaun M. R., Armstrong F. D., McKinstry R. C., Ware R. E., Vichinsky E., Kirkham F. J. Silent cerebral infarcts: a review on a prevalent and progressive cause of neurologic injury in sickle cell anemia. Blood. 2012;119(20):4587–4596. doi: 10.1182/blood-2011-02-272682.
    1. DeBaun M. R., Schatz J., Siegel M. J., et al. Cognitive screening examinations for silent cerebral infarcts in sickle cell disease. Neurology. 1998;50(6):1678–1682. doi: 10.1212/WNL.50.6.1678.
    1. Miller S. T., Macklin E. A., Pegelow C. H., et al. Silent infarction as a risk factor for overt stroke in children with sickle cell anemia: a report from the cooperative study of sickle cell disease. Journal of Pediatrics. 2001;139(3):385–390. doi: 10.1067/mpd.2001.117580.
    1. Ogun G. O., Ebili H., Kotila T. R. Autopsy findings and pattern of mortality in Nigerian sickle cell disease patients. The Pan African Medical Journal. 2014;18, article 30 doi: 10.11604/pamj.2014.18.30.4043.
    1. Platt O. S., Brambilla D. J., Rosse W. F., et al. Mortality in sickle cell disease. Life expectancy and risk factors for early death. The New England Journal of Medicine. 1994;330(23):1639–1644. doi: 10.1056/nejm199406093302303.
    1. Gray A., Anionwu E. N., Davies S. C., Brozovic M. Patterns of mortality in sickle cell disease in the United Kingdom. Journal of Clinical Pathology. 1991;44(6):459–463. doi: 10.1136/jcp.44.6.459.
    1. Paul R. N., Castro O. L., Aggarwal A., Oneal P. A. Acute chest syndrome: sickle cell disease. European Journal of Haematology. 2011;87(3):191–207. doi: 10.1111/j.1600-0609.2011.01647.x.
    1. Bellet P. S., Kalinyak K. A., Shukla R., Gelfand M. J., Rucknagel D. L. Incentive spirometry to prevent acute pulmonary complications in sickle cell diseases. The New England Journal of Medicine. 1995;333(11):699–703. doi: 10.1056/nejm199509143331104.
    1. Charache S., Terrin M. L., Moore R. D., et al. Effect of hydroxyurea on the frequency of painful crises in Sickle cell anemia. The New England Journal of Medicine. 1995;332(20):1317–1322. doi: 10.1056/nejm199505183322001.
    1. Adewoyin A. S., Obieche J. C. Hypertransfusion therapy in sickle cell disease in Nigeria. Advances in Hematology. 2014;2014:8. doi: 10.1155/2014/923593.923593
    1. Crane G. M., Bennett N. E. Priapism in sickle cell anemia: emerging mechanistic understanding and better preventative strategies. Anemia. 2011;2011:6. doi: 10.1155/2011/297364.297364
    1. Nwogoh B., Adewoyin A., Bazuaye G. N., Nwannadi I. A. Prevalence of priapism among male sickle cell disease patients at the University of Benin Teaching Hospital, Benin City. Nigerian Medical Practitioner. 2014;65(1-2):3–7.
    1. Isoa E. M. Current trends in the management of sickle cell disease: an overview. Benin Journal of Postgraduate Medicine. 2009;11(1):50–64. doi: 10.4314/bjpm.v11i1.48855.
    1. Virag R., Bachir D., Lee K., Galacteros F. Preventive treatment of priapism in sickle cell disease with oral and self-administered intracavernous injection of etilefrine. Urology. 1996;47(5):777–781. doi: 10.1016/s0090-4295(96)00027-1.
    1. McDonald M., Santucci R. A. Successful management of stuttering priapism using home self-injections of the alpha-agonist metaraminol. International Braz J Urol. 2004;30(2):121–122. doi: 10.1590/s1677-55382004000200007.
    1. Teloken C., Ribeiro E. P., Chammas M., Jr., Teloken P. E., Souto C. A. V. Intracavernosal etilefrine self-injection therapy for recurrent priapism: one decade of follow-up. Urology. 2005;65(5):p. 1002. doi: 10.1016/j.urology.2004.12.003.
    1. Cherian J., Rao A. R., Thwaini A., Kapasi F., Shergill I. S., Samman R. Medical and surgical management of priapism. Postgraduate Medical Journal. 2006;82(964):89–94. doi: 10.1136/pgmj.2005.037291.
    1. Kato G. J. Priapism in sickle-cell disease: a hematologist's perspective. The Journal of Sexual Medicine. 2012;9(1):70–78. doi: 10.1111/j.1743-6109.2011.02287.x.
    1. Gbadoé A. D., Atakouma Y., Kusiaku K., Assimadi J. K. Management of sickle cell priapism with etilefrine. Archives of Disease in Childhood. 2001;85(1):52–53. doi: 10.1136/adc.85.1.52.
    1. Serjeant G. R., De Ceulaer K., Maude G. H. Stilboestrol and stuttering priapism in homozygous sickle-cell disease. The Lancet. 1985;2(8467):1274–1276.
    1. Burnett A. L., Anele U. A., Trueheart I. N., Strouss J. J., Casella J. F. Randomised Clinical Trial of sildenafil for preventing recurrent ischaemic priapism in Sickle cell disease. American Journal of Medicine. 2014;127(7):664–668.
    1. Lane A., Deveras R. Potential risks of chronic sildenafil use for priapism in sickle cell disease. The Journal of Sexual Medicine. 2011;8(11):3193–3195. doi: 10.1111/j.1743-6109.2011.02440.x.
    1. Pierorazio P. M., Bivalacqua T. J., Burnett A. L. Daily phosphodiesterase type 5 inhibitor therapy as rescue for recurrent ischemic priapism after failed androgen ablation. Journal of Andrology. 2011;32(4):371–374. doi: 10.2164/jandrol.110.011890.
    1. Douglas L., Fletcher H., Serjeant G. R. Penile prostheses in the management of impotence in sickle cell disease. British Journal of Urology. 1990;65(5):533–535. doi: 10.1111/j.1464-410x.1990.tb14803.x.
    1. Mallouh A., Talab Y. Bone and joint infection in patients with sickle cell disease. Journal of Pediatric Orthopaedics. 1985;5(2):158–162. doi: 10.1097/01241398-198505020-00007.
    1. Almeida A., Roberts I. Bone involvement in sickle cell disease. British Journal of Haematology. 2005;129(4):482–490. doi: 10.1111/j.1365-2141.2005.05476.x.
    1. Ebong W. W. Acute osteomyelitis in Nigerians with sickle cell disease. Annals of the Rheumatic Diseases. 1986;45(11):911–915. doi: 10.1136/ard.45.11.911.
    1. Sadat-Ali M. The status of acute osteomyelitis in sickle cell disease. A 15 year review. International Surgery. 1998;83(1):84–87.
    1. Burnett M. W., Bass J. W., Cook B. A. Etiology of osteomyelitis complicating sickle cell disease. Pediatrics. 1998;101(2):296–297. doi: 10.1542/peds.101.2.296.
    1. Barden E. M., Kawchak D. A., Ohene-Frempong K., Stallings V. A., Zemel B. S. Body composition in children with sickle cell disease. The American Journal of Clinical Nutrition. 2002;76(1):218–225.
    1. Booth C., Inusa B., Obaro S. K. Infection in sickle cell disease: a review. International Journal of Infectious Diseases. 2010;14(1):e2–e12. doi: 10.1016/j.ijid.2009.03.010.
    1. Rahim F. The sickle cell disease. Haematology Updates, 2010.
    1. Halasa N. B., Shankar S. M., Talbot T. R., et al. Incidence of invasive pneumococcal disease among individuals with sickle cell disease before and after the introduction of the pneumococcal conjugate vaccine. Clinical Infectious Diseases. 2007;44(11):1428–1433. doi: 10.1086/516781.
    1. Akinyanju O., Johnson A. O. Acute illness in Nigerian children with sickle cell anaemia. Annals of Tropical Paediatrics. 1987;7(3):181–186.
    1. Okuonghae H. O., Nwankwo M. U., Offor E. C. Pattern of bacteraemia in febrile children with sickle cell anaemia. Annals of Tropical Paediatrics. 1993;13(1):55–64.
    1. Obaro S. Pneumococcal infections and sickle cell disease in Africa: does absence of evidence imply evidence of absence? Archives of Disease in Childhood. 2009;94(9):713–716. doi: 10.1136/adc.2008.154815.
    1. Berkley J. A., Lowe B. S., Mwangi I., et al. Bacteremia among children admitted to a rural hospital in Kenya. The New England Journal of Medicine. 2005;352(1):39–47. doi: 10.1056/nejmoa040275.
    1. Roca A., Sigaúque B., Quintó L., et al. Invasive pneumococcal disease in children >5 years of age in rural Mozambique. Tropical Medicine and International Health. 2006;11(9):1422–1431. doi: 10.1111/j.1365-3156.2006.01697.x.
    1. Williams T. N., Uyoga S., Macharia A., et al. Bacteraemia in Kenyan children with sickle-cell anaemia: a retrospective cohort and case-control study. The Lancet. 2009;374(9698):1364–1370. doi: 10.1016/S0140-6736(09)61374-X.
    1. National Immunization Policy Nigeria. National primary health care development agency 2013. 2014.
    1. Fraker P. J., King L. E., Laakko T., Vollmer T. L. The dynamic link between the integrity of the immune system and zinc status. Journal of Nutrition. 2000;130(supplement 5):S1399–S1406.
    1. Temiye E. O., Duke E. S., Owolabi M. A., Renner J. K. Relationship between painful crisis and serum zinc level in children with sickle cell anaemia. Anemia. 2011;2011:7. doi: 10.1155/2011/698586.698586
    1. Idonije B. O., Iribhogbe O. I., Okogun G. R. A. Serum trace element levels in sickle cell disease patients in an urban city in Nigeria. Nature and Science. 2011;9(3):67–71.
    1. Arinola O. G., Olaniyi J. A., Akiibinu M. O. Evaluation of antioxidant levels and trace element status in Nigerian sickle cell disease patients with Plasmodium parasitaemia. Pakistan Journal of Nutrition. 2008;7(6):766–769. doi: 10.3923/pjn.2008.766.769.
    1. Klings E. S., Wyszynski D. F., Nolan V. G., Steinberg M. H. Abnormal pulmonary function in adults with sickle cell anemia. American Journal of Respiratory and Critical Care Medicine. 2006;173(11):1264–1269. doi: 10.1164/rccm.200601-125OC.
    1. Dosunmu A. O., Balogun T. M., Adeyeye O. O., et al. Prevalence of pulmonary hypertension in sickle cell anaemia patients of a tertiary hospital in Nigeria. Nigerian Medical Journal. 2014;55(2):161–165. doi: 10.4103/0300-1652.129661.
    1. Dosunmu A. O., Akinola R. A., Onakoya J. A., et al. Pattern of chronic lung lesions in adults with sickle cell disease in Lagos, Nigeria. Caspian Journal of Internal Medicine. 2013;4(4):754–758.
    1. Fawibe A. E. Sickle cell chronic pulmonary disease among Africans: the need for increased recognition and treatment. African Journal of Respiratory Medicine. 2008:13–16.
    1. Gladwin M. T., Sachdev V., Jison M. L., et al. Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. The New England Journal of Medicine. 2004;350(9):886–895. doi: 10.1056/nejmoa035477.
    1. Issa H., Al-Salem A. H. Hepatobiliary manifestations of sickle cell anemia. Gastroenterology Research. 2010;3(1):1–8. doi: 10.4021/gr2010.01.1332.
    1. Fashola F. A., Otegbayo I. A. Post transfusion viral hepatitis in sickle cell anaemia: retrospective—prospective analysis. Nigerian Journal of Clinical Practice. 2002;5(1):16–19.
    1. Ejeliogu E. U., Okolo S. N., Pam S. D., Okpe E. S., John C. C., Ochoga M. O. Is human immunodeficiency virus still transmissible through blood transfusion in children with sickle cell anaemia in Jos, Nigeria? The British Journal of Medicine and Medical Research. 2014;4(21):3912–3923.
    1. Ogunrinde G. O., Zubair R. O., Mado S. M., Musa S., Umar L. W. Prevalence of nocturnal enuresis in children with homozygous sickle cell disease in zaria. Nigerian Journal of Paediatrics. 2007;34:31–35.
    1. Abdu A., Emokpae M., Uadia P., Kuliya-Gwarzo A. Proteinuria among adult sickle cell anemia patients in Nigeria. Annals of African Medicine. 2011;10(1):34–37. doi: 10.4103/1596-3519.76578.
    1. Aneke J. C., Adegoke A. O., Oyekunle A. A., et al. Degrees of kidney disease in Nigerian adults with sickle-cell disease. Medical Principles and Practice. 2014;23(3):271–274. doi: 10.1159/000361029.
    1. Sharpe C. C., Thein S. L. How I treat renal complications in sickle cell disease. Blood. 2014;123(24):3720–3726. doi: 10.1182/blood-2014-02-557439.
    1. Ataga K. I., Orringer E. P. Renal abnormalities in sickle cell disease. American Journal of Hematology. 2000;63:205–211.
    1. Condon P. I., Serjeant G. R. Ocular findings in homozygous sickle cell anemia in Jamaica. The American Journal of Ophthalmology. 1972;73(4):533–543. doi: 10.1016/0002-9394(72)90005-0.
    1. Koshy M., Entsuah R., Koranda A., et al. Leg ulcers in patients with sickle cell disease. Blood. 1989;74(4):1403–1408.
    1. Bazuaye G. N., Nwannadi A. I., Olayemi E. E. Leg Ulcers in Adult sickle cell disease patients in Benin City, Nigeria. Gomal Journal of Medical Sciences. 2010;8(2):190–194.
    1. Balogun R. A., Obalum D. C., Giwa S. O., Adekoya-Cole T. O., Ogo C. N., Enweluzo G. O. Spectrum of musculo-skeletal disorders in sickle cell disease in Lagos, Nigeria. Journal of Orthopaedic Surgery and Research. 2010;5, article 2 doi: 10.1186/1749-799x-5-2.
    1. Hernigou P., Habibi A., Bachir D., Galacteros F. The natural history of asymptomatic osteonecrosis of the femoral head in adults with sickle cell disease. Journal of Bone and Joint Surgery—Series A. 2006;88(12):2565–2572. doi: 10.2106/jbjs.e.01455.
    1. Madu A. J., Madu A. K., Umar G. K., Ibekwe K., Duru A., Ugwu A. O. Avascular necrosis in sickle cell (homozygous S) patients: predictive clinical and laboratory indices. Nigerian Journal of Clinical Practice. 2014;17(1):86–89. doi: 10.4103/1119-3077.122852.
    1. Hawker H., Neilson H., Hayes R. J., Serjeant G. R. Haematological factors associated with avascular necrosis of the femoral head in homozygous sickle cell disease. British Journal of Haematology. 1982;50(1):29–34. doi: 10.1111/j.1365-2141.1982.tb01887.x.
    1. Mukisi-Mukaza M., Elbaz A., Samuel-Leborgne Y., et al. Prevalence, clinical features, and risk factors of osteonecrosis of the femoral head among adults with sickle cell disease. Orthopedics. 2000;23(4):357–363.
    1. Adekile A. D., Gupta R., Yacoub F., Sinan T., Al-Bloushi M., Haider M. Z. Avascular necrosis of the hip in children with sickle cell disease and high Hb F: magnetic resonance imaging findings and influence of α-thalassemia trait. Acta Haematologica. 2001;105(1):27–31. doi: 10.1159/000046529.
    1. Sickle cell disease in childhood. Standards and guidelines for clinical care. UK Forum on Haemoglobin Disorders, 2010.
    1. Gladwin M. T., Sachdev V. Cardiovascular abnormalities in sickle cell disease. Journal of the American College of Cardiology. 2012;59(13):1123–1133. doi: 10.1016/j.jacc.2011.10.900.
    1. Oguanobi N. I., Ejim E. C., Anisiuba B. C., et al. Clinical and electrocardiographic evaluation of sickle-cell anaemia patients with pulmonary hypertension. ISRN Hematology. 2012;2012:6. doi: 10.5402/2012/768718.768718
    1. Otaigbe B. Prevalence of blood transfusion in sickle cell anaemia patients in South-South Nigeria: a two-year experience. International Journal of Biological and Medical Research. 2013;1(1):13–18.
    1. Al-Saeed H. H., Al-Salem A. H. Principles of blood transfusion in sickle cell anemia. Saudi Medical Journal. 2002;23(12):1443–1448.
    1. Aliyu Z. Y., Tumblin A. R., Kato G. J. Current therapy of sickle cell disease. Haematologica. 2006;91(1):7–11.
    1. Win N. Blood transfusion therapy for Haemoglobinopathies. In: Okpala I. E., editor. Practical Management of Haemoglobinopathies. Blackwell Publishing; 2004. pp. 99–106.
    1. Josephson C. D., Su L. L., Hillyer K. L., Hillyer C. D. Transfusion in the patient with sickle cell disease: a critical review of the literature and transfusion guidelines. Transfusion Medicine Reviews. 2007;21(2):118–133. doi: 10.1016/j.tmrv.2006.11.003.
    1. Vinchinsky E. P. Transfusion therapy in sickle cell disease. 2014, .
    1. Levenson J. L. Psychiatric issues in adults with sickle cell disease. Primary Psychiatry. 2008;15(5):45–49.
    1. Anie K. A., Egunjobi F. E., Akinyanju O. O. Psychosocial impact of sickle cell disorder: perspectives from a Nigerian setting. Globalization and Health. 2010;6, article 2 doi: 10.1186/1744-8603-6-2.
    1. Hilton C., Osborn M., Knight S., Singhal A., Serjeant G. Psychiatric complications of homozygous sickle cell disease among young adults in the Jamaican cohort study. The British Journal of Psychiatry. 1997;170:69–76. doi: 10.1192/bjp.170.1.69.
    1. Rappaport V. J., Velazquez M., Williams K. Hemoglobinopathies in pregnancy. Obstetrics and Gynecology Clinics of North America. 2004;31(2):287–317. doi: 10.1016/j.ogc.2004.03.006.
    1. Naik R. P., Lanzkron S. Baby on board: what you need to know about pregnancy in the hemoglobinopathies. Hematology. 2012;2012:208–214.
    1. Afolabi B. B., Iwuala N. C., Iwuala I. C., Ogedengbe O. K. Morbidity and mortality in sickle cell pregnancies in Lagos, Nigeria: a case control study. Journal of Obstetrics & Gynaecology. 2009;29(2):104–106. doi: 10.1080/01443610802667112.
    1. Omole-Ohonsi A., Ashimi O. A., Aiyedun T. A. Preconception care and sickle cell anemia in pregnancy. Journal of Basic and Clinical Reproductive Sciences. 2012;1(1):12–18. doi: 10.4103/2278-960x.104290.
    1. Al-Samak Z. M., Al-Falaki M. M., Pasha A. A. Assessment of perioperative transfusion therapy and complications in sickle cell disease patients undergoing surgery. Middle East Journal of Anesthesiology. 2008;19(5):983–995.
    1. Marchant W. A., Walker I. Anaesthetic management of the child with sickle cell disease. Paediatric Anaesthesia. 2003;13(6):473–489. doi: 10.1046/j.1460-9592.2003.01026.x.
    1. Vichinsky E. P., Haberkern C. M., Neumayr L., et al. A comparison of conservative and aggressive transfusion regimens in the perioperative management of sickle cell disease. The New England Journal of Medicine. 1995;333(4):206–213. doi: 10.1056/nejm199507273330402.
    1. Dix H. M. New advances in the treatment of sickle cell disease: focus on perioperative significance. Journal of the American Association of Nurse Anesthetists. 2001;69(4):281–286.
    1. Losco P., Nash G., Stone P., Ventre J. Comparison of the effects of radiographic contrast media on dehydration and filterability of red blood cells from donors homozygous for hemoglobin A or hemoglobin S. American Journal of Hematology. 2001;68(3):149–158. doi: 10.1002/ajh.1171.
    1. Kotila T. R. Guidelines for the diagnosis of the haemoglobinopathies in Nigeria. Annals of Ibadan Postgraduate Medicine. 2011;8(1):25–29. doi: 10.4314/aipm.v8i1.63954.
    1. Daniel Y. Haemoglobinopathy diagnostic tests: blood counts, sickle solubility test, haemoglobin electrophoresis and high-performance liquid chromatography. In: Okpala I. E., editor. Practical Management of Haemoglobinopathies. Blackwell Publishing; 2004. pp. 10–19.
    1. Bain B. J. Haemoglobinopathy diagnosis: algorithms, lessons and pitfalls. Blood Reviews. 2011;25(5):205–213. doi: 10.1016/j.blre.2011.04.001.
    1. Clarke G. M., Higgins T. N. Laboratory investigation of hemoglobinopathies and thalassemias: review and update. Clinical Chemistry. 2000;46(8, part 2):1284–1290.
    1. Emmanuelchide O., Charle O., Uchenna O. Hematological parameters in association with outcomes in sickle cell anemia patients. Indian Journal of Medical Sciences. 2011;65(9):393–398. doi: 10.4103/0019-5359.108955.
    1. Adegoke S. A., Kuti B. P. Evaluation of clinical severity of sickle cell anaemia in Nigerian children. Journal of Applied Hematology. 2013;4(2):58–64.
    1. Quinn C. T., Rogers Z. R., Buchanan G. R. Survival of children with sickle cell disease. Blood. 2004;103(11):4023–4027. doi: 10.1182/blood-2003-11-3758.
    1. Wierenga K. J. J., Hambleton I. R., Lewis N. A. Survival estimates for patients with homozygous sickle-cell disease in Jamaica: a clinic-based population study. The Lancet. 2001;357(9257):680–683. doi: 10.1016/s0140-6736(00)04132-5.
    1. Chijioke A., Kolo P. M. The longevity and clinical pattern of adult sickle cell anaemia in Ilorin. European Journal of Scientific Research. 2009;32(4):528–532.
    1. Angastiniotis M., Kyriakidou S., Hadjiminas M. How thalassaemia was controlled in Cyprus. World Health Forum. 1986;7(3):291–297.
    1. Durosinmi M. A., Odebiyi A. I., Adediran I. A., Akinola N. O., Adegorioye D. E., Okunade M. A. Acceptability of prenatal diagnosis of sickle cell anaemia (SCA) by female patients and parents of SCA patients in Nigeria. Social Science and Medicine. 1995;41(3):433–436. doi: 10.1016/0277-9536(94)00361-v.
    1. Adeyemi A. S., Adekanle D. A. Knowledge and attitude of female health workers towards prenatal diagnosis of sickle cell disease. Nigerian Journal of Medicine. 2007;16(3):268–270.
    1. Kagu M. B., Abjah U. A., Ahmed S. G. Awareness and acceptability of prenatal diagnosis of sickle cell anaemia among health professionals and students in North Eastern Nigeria. Nigerian Journal of Medicine. 2004;13(1):48–51.
    1. World Health Organisation. Guidelines for the Control of Haemoglobin Disorders. Sardinia, Italy: WHO; 1994.
    1. Akodu S. O., Diaku-Akinwumi I. N., Njokanma O. F. Age at diagnosis of sickle cell anaemia in lagos, Nigeria. Mediterranean Journal of Hematology and Infectious Diseases. 2013;5(1) doi: 10.4084/mjhid.2013.001.e2013001
    1. Olatona F. A., Odeyemi K. A., Onajole A. T., Asuzu M. C. Effects of health education on knowledge and attitude of youth corps members to sickle cell disease and its screening in Lagos State. Journal of Community Medicine & Health Education. 2012;2(article 163) doi: 10.4172/2161-0711.1000163.
    1. Galadanci N., Wudil B. J., Balogun T. M., et al. Current sickle cell disease management practices in Nigeria. International Health. 2014;6(1):23–28. doi: 10.1093/inthealth/iht022.
    1. Oyekunle A. A. Haemopoietic stem cell transplantation: prospects and challenges in Nigeria. Annals of Ibadan Postgraduate Medicine. 2006;4(1):17–27.
    1. Bazuaye N., Nwogoh B., Ikponmwen D., et al. First successful allogeneic hematopoietic stem cell transplantation for a sickle cell disease patient in a low resource country (Nigeria): a case report. Annals of Transplantation. 2014;19(1):210–213. doi: 10.12659/aot.890248.
    1. Akinyanju O. O., Otaigbe A. I., Ibidapo M. O. O. Outcome of holistic care in Nigerian patients with sickle cell anaemia. Clinical and Laboratory Haematology. 2005;27(3):195–199. doi: 10.1111/j.1365-2257.2005.00683.x.
    1. Okpala I. E. Sickle cell crisis. In: Okpala I. E., editor. Practical Management of Haemoglobinopathies. Blackwell Publishing; 2004. pp. 63–71.
    1. Okpala I., Thomas V., Westerdale N., et al. The comprehensive care of sickle cell disease. European Journal of Haematology. 2002;68(3):157–162. doi: 10.1034/j.1600-0609.2002.01523.x.
    1. Makani J., Ofori-Acquah S. F., Nnodu O., Wonkam A., Ohene-Frempong K. Sickle cell disease: new opportunities and challenges in Africa. The Scientific World Journal. 2013;2013:16. doi: 10.1155/2013/193252.193252
    1. Oniyangi O., Omari A. A. A. Malaria chemoprophylaxis in sickle cell disease. The Cochrane Library. 2009;1:1–18.
    1. Ibe E. O., Ezeoke A. C. J., Emeodi I., et al. Electrolyte profile and prevalent causes of sickle cell crisis in Enugu, Nigeria. African Journal of Biochemistry Research. 2009;3(11):370–374.
    1. Bolarinwa R. A., Akinola N. O., Aboderin O. A., Durosinmi M. A. The role of malaria in vaso-occlusive crisis of adult patients with sickle cell disease. Journal of Medicine and Medical Sciences. 2010;1:407–411.
    1. Kotila R., Okesola A., Makanjuola O. Asymptomatic malaria parasitaemia in sickle-cell disease patients: how effective is chemoprophylaxis? Journal of Vector Borne Diseases. 2007;44(1):52–55.
    1. Ware R. E. How I use hydroxyurea to treat young patients with sickle cell anemia. Blood. 2010;115(26):5300–5311. doi: 10.1182/blood-2009-04-146852.
    1. Davies S. C., Gilmore A. The role of hydroxyurea in the management of sickle cell disease. Blood Reviews. 2003;17(2):99–109. doi: 10.1016/S0268-960X(02)00074-7.
    1. Davies S. C., Roberts I. A. G. Bone marrow transplant for sickle cell disease—an update. Archives of Disease in Childhood. 1996;75(1):3–6. doi: 10.1136/adc.75.1.3.
    1. Roberts I. Current status of allogeneic transplantation for haemoglobinopathies. British Journal of Haematology. 1997;98(1):1–7. doi: 10.1046/j.1365-2141.1997.1332948.x.
    1. Shenoy S. Hematopoietic stem cell transplantation for sickle cell disease: current practice and emerging trends. Hematology. 2011;2011:273–279. doi: 10.1182/asheducation-2011.1.273.
    1. De Franceschi L. Pathophysiology of sickle cell disease and new drugs for the treatment. Mediterranean Journal of Hematology and Infectious Diseases. 2009;1(1)
    1. De Franceschi L., Corrocher R. Established and experimental treatments for sickle cell disease. Haematologica. 2004;89(3):348–356.
    1. Ataga K. I., Stocker J. Senicapoc (ICA17043): a potential therapy for the prevention and treatment of hemolysis-associated complications in sickle cell anemia. Expert Opinion on Investigational Drugs. 2009;18(2):231–239. doi: 10.1517/13543780802708011.
    1. Ataga K. I., Smith W. R., De Castro L. M., et al. Efficacy and safety of the Gardos channel blocker, senicapoc (ICA-17043), in patients with sickle cell anemia. Blood. 2008;111(8):3991–3997. doi: 10.1182/blood-2007-08-110098.
    1. Okpala I. E. New therapies for sickle cell disease. Hematology/Oncology Clinics of North America. 2005;19(5):975–987. doi: 10.1016/j.hoc.2005.08.004.
    1. Stuart M. J., Nagel R. L. Sickle-cell disease. The Lancet. 2004;364(9442):1343–1360. doi: 10.1016/s0140-6736(04)17192-4.
    1. Walters M. C. Stem cell therapy for sickle cell disease: transplantation and gene therapy. Hematology. 2005;2005(1):66–73. doi: 10.1182/asheducation-2005.1.66.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir